Compare CRDF & HOVR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CRDF | HOVR |
|---|---|---|
| Founded | 1999 | 2013 |
| Country | United States | Canada |
| Employees | N/A | 30 |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Blank Checks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 86.8M | 80.6M |
| IPO Year | 2012 | N/A |
| Metric | CRDF | HOVR |
|---|---|---|
| Price | $0.85 | $1.75 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 3 |
| Target Price | $9.63 | ★ $10.33 |
| AVG Volume (30 Days) | ★ 1.6M | 1.2M |
| Earning Date | 05-07-2026 | 04-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 27.37 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $365,993.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 49.61 | N/A |
| 52 Week Low | $0.76 | $1.16 |
| 52 Week High | $3.31 | $4.18 |
| Indicator | CRDF | HOVR |
|---|---|---|
| Relative Strength Index (RSI) | 27.50 | 39.03 |
| Support Level | N/A | $1.44 |
| Resistance Level | $2.03 | $2.01 |
| Average True Range (ATR) | 0.07 | 0.16 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 7.93 | 20.87 |
Cardiff Oncology Inc is a clinical-stage biotechnology company that leverages PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies for various cancers with unmet medical needs. The company focuses on targeting tumor vulnerabilities with treatment combinations of onvansertib, its oral and selective PLK1 inhibitor, and standard-of-care (SoC) therapeutics. The firm's clinical program pipeline focuses on indications such as RAS-mutated metastatic colorectal cancer (mCRC), investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC), metastatic triple negative breast cancer (mTNBC), and Chronic Myelomonocytic Leukemia (CMML). Geographically, it operates only in the United States.
New Horizon Aircraft Ltd is an aerospace Original Equipment Manufacturer that is designing and building a next-generation hybrid electric vertical take-off and landing aircraft for the regional air mobility market. Its aircraft will offer a more efficient way to move people and goods at a regional scale, help to connect remote communities, and advance its ability to deal with an increasing number of climate-related natural disasters such as wildfires, floods, and droughts. The company aims to deliver a hybrid electric 7-seat aircraft, called the Cavorite X7, that can take off and land vertically like and helicopter.